Table 2. Efficacy of PD-1 and apatinib combination treatment in pts with GC/EGJC.
| Evaluation | Value |
|---|---|
| RECIST v1.1 tumor evaluation | |
| CR | 1 |
| PR | 4 |
| SD ≥6 weeks | 7 |
| PD | 7 |
| Not evaluable | 5 |
| ORR in evaluable patients | 26.30% |
| DCR in evaluable patients | 63.20% |
| Median time to response | 1.7 months |
| Duration of response | |
| KM median | 3.0 months |
| PFS | |
| KM median | 3.0 months |
| OS | |
| KM median | NR |
GC, gastric cancer; EGJC, esophagogastric junction cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; KM, Kaplan-Meier; PFS, progression-free survival; OS, overall survival; NR, not reached.